Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Viatris Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $41.3, while Viatris Inc trades at $16.6 (market cap $19.44B). The key difference: Viatris Inc pays a 2.88% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none, and Viatris Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| GPTY | VTRS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $17.39 |
52-Week Low | $34.73 | $8.74 |
Market Cap | — | $19.44B |
Enterprise Value | — | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $41.41, down 3.97% on the day, with technical indicators showing a neutral to bearish bias. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.30 to $0.38. Support and resistance levels cluster tightly around $43-$46, indicating potential for near-term consolidation. Recent news highlights focus on its option-income strategy and comparisons to peers like ULTY.
The outlook balances high yield potential against market volatility risks. Investment appeal centers on AI/tech exposure coupled with income generation, but reliance on semiconductor momentum and option premiums introduces volatility. Key risks include NAV erosion from the covered call strategy and sector concentration, requiring careful risk assessment for income-focused investors.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
